title: Drugs for rapid treatment of very high blood pressure during pregnancy.
abstract: BACKGROUND
  Very high blood pressure during pregnancy poses a serious threat to women and their fetuses. The use of drugs to lower blood pressure may reduce this risk.
  
  
  OBJECTIVE
  The objective of this review was to compare different antihypertensive drugs used for rapid treatment of severe hypertension during pregnancy.
  
  
  METHODS
  We searched the Cochrane Pregnancy and Childbirth Group trials register and the Cochrane Controlled Trials Register.
  
  
  METHODS
  
  
  
  METHODS
  All randomised trials. Quasi random designs were excluded.
  
  
  METHODS
  Women with severe hypertension during pregnancy. Women postpartum at trial entry were excluded.
  
  
  METHODS
  Comparisons of one antihypertensive agent with another.
  
  
  RESULTS
  For the women: blood pressure control, eclampsia, serious maternal morbidity (such as kidney failure and liver failure), Caesarean section, and use of health service resources (such as admission to hospital or intensive care unit). For the baby: death, serious neonatal morbidity, infant and child development, and use of health service resources (such as admission to a special care nursery).
  
  
  METHODS
  Data were extracted independently by two reviewers to assess eligibility and describe the trial characteristics, and by one reviewer for the meta-analyses. Discrepancies were resolved by discussion. There was no blinding of authorship or results. Whenever possible, unpublished data were sought from investigators.
  
  
  RESULTS
  Thirteen of the 14 trials included in this review were small (range 19-627 women). Of the eight comparisons, five included hydralazine. Diazoxide given as 75mg bolus injections appears to be associated with profound hypotension requiring treatment, and ketanserin is less effective than hydralazine at reducing blood pressure. There is no other evidence that any one of the other antihypertensive agents is better than another for women with severe hypertension during pregnancy.
  
  
  CONCLUSIONS
  Until better evidence is available, the choice of antihypertensive should depend on the experience and familiarity of an individual clinician with a particular drug, and on what is known about adverse maternal and fetal side-effects. Exceptions are diazoxide and ketanserin, which are probably not good choices.
authors.affiliation: Resource Centre for Randomised Trials, Institute of Health Sciences, Old Road, Headington, Oxford, UK, OX3 7LF. lelia.duley@ndm.ox.ac.uk
authors.forename: L
authors.initials: L
authors.lastname: Duley
authors.forename: D J
authors.initials: DJ
authors.lastname: Henderson-Smart
mesh_terms: D000959:Antihypertensive Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D011247:Pregnancy; D011249:Pregnancy Complications, Cardiovascular / Q000188:drug therapy*
chemical_list: D000959:Antihypertensive Agents